Monitor for Part B data readout and any subsequent financing needs given the company's $3M market cap. The safety profile is encouraging but efficacy data from Part B will be the next catalyst.
Price Chart
Executive Summary
Clearmind Medicine announced completion of dosing for all 24 participants in Part A of its Phase I/II clinical trial for CMND-100, a treatment for Alcohol Use Disorder. The trial enrolled rapidly across four sites including Yale and Johns Hopkins, and interim results from the first three cohorts showed a strong safety profile. This is a routine operational milestone for a clinical-stage biotech with no financial data or efficacy results disclosed.
Key Facts
- Completed dosing for all 24 participants in Cohorts 1-4 of Part A of the Phase I/II trial for CMND-100
- Trial sites include Yale School of Medicine, Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center
- Interim results from first three cohorts show a strong safety profile
- Company has 19 patent families including 31 granted patents
Financial Impact
Not specified
Risk Factors
- Clinical-stage biotech with no approved products or revenue
- Phase I/II trial still ongoing; efficacy and safety remain unproven
- Potential need for additional capital to fund further development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-069044 |
| Document: ea029492102ex99-1.htm | 0001213900-26-069044 |
| Document: 0001213900-26-069044-index-headers.html | 0001213900-26-069044 |
| Document: 0001213900-26-069044-index.html | 0001213900-26-069044 |
| Document: 0001213900-26-069044.txt | 0001213900-26-069044 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $5.92 | awaiting T+60 | — | $5.95 (+0.47%) |
Oct 27, 2026 today | Press Release | $6.50 | awaiting T+60 | — | $5.95 (−8.50%) |
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $5.95 (+0.87%) |
Oct 13, 2026 14d ago | 6-K | $6.23 | awaiting T+60 | — | $5.95 (−4.53%) |
Oct 8, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $5.95 (−9.88%) |
Oct 7, 2026 20d ago | 6-K | $6.60 | awaiting T+60 | — | $5.95 (−9.88%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $5.95 (+599.72%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $5.95 (+599.72%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $5.95 (−13.35%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $5.95 (+530.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers